Stock Graphs and Charts

This is a complete list of financial data submitted by Halozyme Therapeutics, Inc. to the Securities and Exchange Commission (SEC) in their recent 10K and 10Q filings. These terms are taken from the XBRL portion of the filings.

Click on a term to see historical data and generate a time series chart from the historical filings.

Term
A2017 Federaltaxrate
A2018 Federaltaxrate
Accounts And Other Receivables Net Current
Accounts Payable Current
Accountsreceivablefromcollaborators
Accountsreceivablefromproductsales
Accountsreceivablefromproductsalestocollaborators
Accountsreceivablefromroyalties
Accounts Receivable Gross Current
Accounts Receivable Net Current
Accretion Amortization Of Discounts And Premiums Investments
Accrued Liabilities And Other Liabilities
Accrued Liabilities Current
Accrued Liabilities Current And Noncurrent
Accruedmanufacturingexpenses
Accrued Outsourced Research And Development Expenses Current
Accrued Outsourced Researchand Development Expenses Long Term
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
Accumulated Other Comprehensive Income Loss Net Of Tax
Additional Achievement Of Development And Regulatory Milestones
Additional Achievementof Regulatory Milestones
Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets
Additional Maximum Payments Upon Achievement Of Development And Regulatory Milestones For Each Product Targeting Treatment Of Any Of Three Orphan Indications
Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones
Additional Maximum Proceeds Receivable From Partner Of License And Collaborative Agreement Upon Achievement Of Clinical Development Milestones
Additional Paid In Capital Common Stock
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Allocated Share Based Compensation Expense
Allocated Share Based Compensation Expense Per Share Basic And Diluted
Allowancefor Distribution Feesand Discounts
Allowance For Doubtful Accounts Receivable Current
Amortization Of Debt Discount Premium
Amortization Of Financing Costs
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Assets
Assets Current
Assets Fair Value Disclosure
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
Available For Sale Maturities Debt Maturities Next Twelve To Eighteen Months Fair Value
Available For Sale Securities
Available For Sale Securities Amortized Cost
Available For Sale Securities Continuous Unrealized Loss Position Fair Value
Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
Available For Sale Securities Current
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
Available For Sale Securities Debt Maturities Within One Year Fair Value
Available For Sale Securities Fair Value Disclosure
Available For Sale Securities Gross Realized Gain Loss Net
Availableforsale Securities Gross Unrealized Gain
Available For Sale Securities Gross Unrealized Gains
Available For Sale Securities Gross Unrealized Loss
Available For Sale Securities Gross Unrealized Losses1
Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
Available For Sale Securities Sold
Capital Expenditures Incurred But Not Yet Paid
Capital Leased Assets Gross
Capital Lease Obligations Incurred
Capital Lease Obligations Noncurrent
Cash And Cash Equivalents At Carrying Value
Cash And Cash Equivalents Period Increase Decrease
Cashcashequivalentsandrestrictedcash
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Common Shares Outstanding
Common Stock Capital Shares Reserved For Future Issuance
Common Stock Par Or Stated Value Per Share
Common Stock Shares Authorized
Common Stock Shares Issued
Common Stock Shares Outstanding
Common Stock Value
Comprehensive Income Net Of Tax
Concentration Risk Percentage1
Contingentmilestonepayment
Contract With Customer Asset Net
Cost Of Goods Sold
Costs And Expenses
Cumulative Effect Of New Accounting Principle In Period Of Adoption
Current Federal Tax Expense Benefit
Current State And Local Tax Expense Benefit
Debt Instrument Carrying Amount
Debt Instrument Final Payment
Debt Instrument Unamortized Discount
Deferred Federal Income Tax Expense Benefit
Deferred Foreign Income Tax Expense Benefit
Deferred Rent Credit
Deferred Rent Credit Noncurrent
Deferred Revenue
Deferred Revenue Current
Deferred Revenue Noncurrent
Deferred Revenue Relating To Upfront Payment License Fees
Deferred Revenue Revenue Recognized1
Deferred State And Local Income Tax Expense Benefit
Deferredtaxassetexcludingamountfor AMT
Deferred Tax Assets Deferred Income
Deferred Tax Assets Gross
Deferred Tax Assets In Process Research And Development
Deferred Tax Assets Liabilities Net
Deferred Tax Assets Net
Deferred Tax Assets Operating Loss Carryforwards
Deferred Tax Assets Other
Deferred Tax Assets Property Plant And Equipment
Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
Deferred Tax Assets Tax Credit Carryforwards Research
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Deferred Tax Assets Valuation Allowance
Deferred Tax Liabilities Noncurrent
Deferred Tax Liabilities Property Plant And Equipment
Defined Contribution Plan Employer Discretionary Contribution Amount
Depreciation And Amortization
Depreciation Depletion And Amortization
Earnings Per Share Basic
Earnings Per Share Basic And Diluted
Earnings Per Share Diluted
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
Employee Related Liabilities Current
Employee Service Share Based Compensation Cash Received From Exercise Of Stock Options
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
Employee Service Share Based Compensation Tax Benefit From Compensation Expense
Fair Value Assets Level1 To Level2 Transfers Amount
Foreignbasedoperations
Foreign Currency Transaction Gain Loss Unrealized
Gain Loss On Sale Of Property Plant Equipment
Gross Profit
Hypothetical License Revenueunder ASC606
Hypothetical Royalty Revenueunder ASC606
Impairment Of Investments
Impairment Of Long Lived Assets Held For Use
Income Loss From Continuing Operations Before Income Taxes Domestic
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
Income Loss From Continuing Operations Before Income Taxes Foreign
Income Loss From Extraordinary Items Net Of Tax Per Basic And Diluted Share
Income Taxes Paid
Income Tax Expense Benefit
Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
Income Tax Reconciliation Change In Enacted Tax Rate
Income Tax Reconciliation Deductions
Income Tax Reconciliation Foreign Income Tax Rate Differential
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
Income Tax Reconciliation Nondeductible Expense Other
Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
Income Tax Reconciliation State And Local Income Taxes
Income Tax Reconciliation Tax Credits Research
Increase Decrease In Accounts Payable And Accrued Liabilities
Increase Decrease In Accounts Receivable
Increase Decrease In Deferred Charges
Increase Decrease In Deferred Rent
Increase Decrease In Deferred Revenue
Increase Decrease In Inventories
Increase Decrease In Other Deferred Liability
Increase Decrease In Other Operating Liabilities
Increase Decrease In Prepaid Deferred Expense And Other Assets
Increase Decrease In Restricted Cash
Incremental Common Shares Attributable To Share Based Payment Arrangements
Interest Expense
Interest Expense Debt
Interest Income Expense Net
Interest Paid
Inventory Finished Goods
Inventory Finished Goods Net Of Reserves
Inventory Net
Inventory Raw Materials
Inventory Raw Materials Net Of Reserves
Inventory Work In Process
Inventory Work In Process Net Of Reserves
Inventory Write Down
Investment Income Net
Investments Fair Value Disclosure
Issuance Of Common Stock Pursuant To Exercise Of Warrants Net Value
Liabilities And Stockholders Equity
Liabilities Current
License And Services Revenue
Long Term Debt
Long Term Debt Current
Long Term Debt Fair Value
Long Term Debt Including Interest Gross
Long Term Debt Interest Gross
Long Term Debt Maturities Repayments In Next Twelve Months
Long Term Debt Maturities Repayments In Year Five
Long Term Debt Maturities Repayments In Year Four
Long Term Debt Maturities Repayments In Year Three
Long Term Debt Maturities Repayments In Year Two
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
Long Term Debt Maturities Repayments Of Principal In Year Five
Long Term Debt Maturities Repayments Of Principal In Year Four
Long Term Debt Maturities Repayments Of Principal In Year Three
Long Term Debt Maturities Repayments Of Principal In Year Two
Long Term Debt Noncurrent
Manufacturingcostspreviouslyrecordedasresearchanddevelopment
Manufacturingcostspreviouslyrecordedforbulkr Hu PH20
Marketable Securities
Net Cash Provided By Used In Financing Activities
Net Cash Provided By Used In Financing Activities Continuing Operations
Net Cash Provided By Used In Investing Activities
Net Cash Provided By Used In Investing Activities Continuing Operations
Net Cash Provided By Used In Operating Activities
Net Cash Provided By Used In Operating Activities Continuing Operations
Net Income Loss
New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1
New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
Numberofmanufacturers
Number Of Operating Segments
Numberoftargetsoptionaladditionalfeescontingent
Operating Expenses
Operating Income Loss
Operating Leases Future Minimum Payments Due
Operating Leases Future Minimum Payments Due Current
Operating Leases Future Minimum Payments Due In Five Years
Operating Leases Future Minimum Payments Due In Four Years
Operating Leases Future Minimum Payments Due In Three Years
Operating Leases Future Minimum Payments Due In Two Years
Operating Leases Future Minimum Payments Due Thereafter
Operating Leases Rent Expense Net
Operating Loss Carryforwards
Other Accrued Liabilities Current
Other Accrued Liabilities Noncurrent
Other Assets
Other Comprehensive Income Loss Before Tax
Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax
Other Comprehensive Income Loss Net Of Tax
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
Othercontractassets
Other Income
Other Liabilities Noncurrent
Other Noncash Expense
Other Noncash Income
Other Noncash Income Expense
Other Nonoperating Income Expense
Other Operating Activities Cash Flow Statement
Other Prepaid Expense Current
Other Restructuring Costs
Other Than Temporary Impairment Losses Investments Availableforsale Securities
Paid In Kind Interest
Payments For Restructuring
Payments Related To Tax Withholding For Share Based Compensation
Payments To Acquire Available For Sale Securities
Payments To Acquire Marketable Securities
Payments To Acquire Property Plant And Equipment
Preferred Stock Par Or Stated Value Per Share
Preferred Stock Shares Authorized
Preferred Stock Shares Issued
Preferred Stock Shares Outstanding
Preferred Stock Value
Prepaid Expense And Other Assets
Prepaid Expense And Other Assets Current
Prepaid Expense And Other Assets Noncurrent
Prepaid Expense Current
Prepaidmanufacturingexpense
Prepaidresearchanddevelopment
Prior Period Reclassification Adjustment
Proceeds And Excess Tax Benefit From Sharebased Compensation
Proceeds From Debt Net Of Issuance Costs
Proceeds From Issuance Of Common Stock
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
Proceeds From Partner Of License And Collaborative Agreement
Proceeds From Sale And Maturity Of Marketable Securities
Proceeds From Sale Of Available For Sale Securities
Proceeds From Sale Of Property Plant And Equipment
Proceeds From Stock Options Exercised
Proceeds From Warrant Exercises
Property Plant And Equipment Gross
Property Plant And Equipment Net
Purchase Of Common Stock By Affiliates
Purchase Of Common Stock By Affiliates Amount
Recognition Of Deferred Revenue
Repayments Of Secured Debt
Research And Development Expense
Restricted Cash And Cash Equivalents Noncurrent
Restrictedstockawardholderexerciseprice
Restructuring And Related Cost Number Of Positions Eliminated Period Percent
Restructuring Reserve Current
Restructuring Reserve Settled With Cash
Retained Earnings Accumulated Deficit
Revenueamortizationoflicensepayments
Revenue From Grants
Revenues
Royalty Revenue
Sale Of Stock Price Per Share
Sales Revenue Goods Net
Selling General And Administrative Expense
Severance Costs1
Share Based Compensation
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
Share Based Compensation Arrangement By Share Based Payment Award Number Of Plans
Share Based Compensation Arrangement By Share Based Payment Award Options Exercise Price Percent Of Share Price
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent
Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Share Price
Shares Float
Shares Used In Computing Basic And Diluted Net Loss Per Share
Stockholders Equity
Stock Issued During Period Shares New Issues
Stock Issued During Period Shares New Issues To Underwriter
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
Stock Issued During Period Shares Share Based Compensation
Stock Issued During Period Shares Stock Options Exercised
Stock Issued During Period Value New Issues
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
Stock Issued During Period Value Stock Options Exercised
Straight Line Rent
Undistributed Earnings Of Foreign Subsidiaries
Unrecognized Tax Benefits
Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
Unrecognized Tax Benefits That Would Impact Effective Tax Rate
Unrecognized Tax Benefitsthat Would Impact Effective Tax Ratenovaluationallowance
Valuation Allowance Deferred Tax Asset Change In Amount
Valuation Allowances And Reserves Balance
Valuation Allowances And Reserves Charged To Cost And Expense
Valuation Allowances And Reserves Deductions
Weighted Average Number Diluted Shares Outstanding Adjustment
Weighted Average Number Of Diluted Shares Outstanding
Weighted Average Number Of Share Outstanding Basic And Diluted
Weighted Average Number Of Shares Outstanding Basic

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)

Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good day, ladies and gentlemen and welcome to the Halozyme Investor Call. We now have all of have speakers in conference. Please be aware that your line is in listen-only mode. At the conclusion on today’s presentation, we will open the floor for questions, [Operator Instructions]. (4-0)

Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

2018-07-26 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) posted second-quarter 2018 adjusted earnings of $2.07 per share, which came in higher than the year-ago earnings of $1.56 by 32.7%. Earnings also beat the Zacks Consensus Estimate of $1.69. Strong product revenues drove the bottom line in the quarter. (1-0)

Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis

2018-07-16 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. (4-3)

Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha
Good afternoon and welcome to the Halozyme Therapeutics First Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this call is being recorded. (52-0)

CUSIP: 40637H109